Cargando…

MiR-423-5p activated by E2F1 promotes neovascularization in diabetic retinopathy by targeting HIPK2

BACKGROUND: Diabetic retinopathy (DR) is a diabetic complication and the primary cause of blindness in the world. However, the treatments of DR are challenging given its complicated pathogenesis. Here, we investigated the molecular mechanisms of DR by focusing on the function of E2F1/miR-423-5p/HIPK...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Qing, Zhao, Yinu, Sun, Hongjing, Xu, Jia, Li, Wenjie, Gao, Limo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715594/
https://www.ncbi.nlm.nih.gov/pubmed/34963484
http://dx.doi.org/10.1186/s13098-021-00769-7
_version_ 1784624157908008960
author Xiao, Qing
Zhao, Yinu
Sun, Hongjing
Xu, Jia
Li, Wenjie
Gao, Limo
author_facet Xiao, Qing
Zhao, Yinu
Sun, Hongjing
Xu, Jia
Li, Wenjie
Gao, Limo
author_sort Xiao, Qing
collection PubMed
description BACKGROUND: Diabetic retinopathy (DR) is a diabetic complication and the primary cause of blindness in the world. However, the treatments of DR are challenging given its complicated pathogenesis. Here, we investigated the molecular mechanisms of DR by focusing on the function of E2F1/miR-423-5p/HIPK2/HIF1α/VEGF axis. METHODS: Cultured retinal endothelial cells (hRMECs, hRECs) were treated with 25 mM glucose to mimic the high glucose-induced DR in vitro. Streptozotocin (STZ) was injected into mice to induce DR in mice. qRT-PCR, western blotting, immunohistochemistry, and ELISA were employed to measure levels of E2F1, miR-423-5p, HIPK2, HIF1α, and VEGF. H&E staining was utilized to examine retinal neovascularization. CCK-8 assay, transwell assay, and vascular tube formation assay were used to assess the cell viability, migration, and angiogenesis. Dual luciferase assay was performed to validate interactions between E2F1 and miR-423-5p, miR-423-5p and HIPK2. RESULTS: HG treatment increased the cell viability, migration, and angiogenesis accompanied by upregulation of E2F1, miR-423-5p, HIF1α, and VEGF levels, but reduction in HIPK2 expression. Knockdown of E2F1 or miR-423-5p suppressed the HG-induced increases in cell viability, migration, and angiogenesis. E2F1 transcriptionally activated miR-423-5p expression and miR-423-5p mimics blocked the effects of E2F1 knockdown on angiogenesis. Moreover, miR-423-5p directly targeted HIPK2 to disinhibit HIF1α/VEGF signaling. Knockdown of HIPK2 reversed the effects of miR-423-5p inhibitor on cell viability, migration, and angiogenesis. Knockdown of E2F1 suppressed neovascularization during DR in vivo. CONCLUSIONS: E2F1 activates miR-423-5p transcription during DR to promote angiogenesis via suppressing HIPK2 expression to disinhibit HIF1α/VEGF signaling. Strategies targeting E2F1/miR-423-5p/HIPK2 axis could be potentially used for DR treatment.
format Online
Article
Text
id pubmed-8715594
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87155942022-01-05 MiR-423-5p activated by E2F1 promotes neovascularization in diabetic retinopathy by targeting HIPK2 Xiao, Qing Zhao, Yinu Sun, Hongjing Xu, Jia Li, Wenjie Gao, Limo Diabetol Metab Syndr Research BACKGROUND: Diabetic retinopathy (DR) is a diabetic complication and the primary cause of blindness in the world. However, the treatments of DR are challenging given its complicated pathogenesis. Here, we investigated the molecular mechanisms of DR by focusing on the function of E2F1/miR-423-5p/HIPK2/HIF1α/VEGF axis. METHODS: Cultured retinal endothelial cells (hRMECs, hRECs) were treated with 25 mM glucose to mimic the high glucose-induced DR in vitro. Streptozotocin (STZ) was injected into mice to induce DR in mice. qRT-PCR, western blotting, immunohistochemistry, and ELISA were employed to measure levels of E2F1, miR-423-5p, HIPK2, HIF1α, and VEGF. H&E staining was utilized to examine retinal neovascularization. CCK-8 assay, transwell assay, and vascular tube formation assay were used to assess the cell viability, migration, and angiogenesis. Dual luciferase assay was performed to validate interactions between E2F1 and miR-423-5p, miR-423-5p and HIPK2. RESULTS: HG treatment increased the cell viability, migration, and angiogenesis accompanied by upregulation of E2F1, miR-423-5p, HIF1α, and VEGF levels, but reduction in HIPK2 expression. Knockdown of E2F1 or miR-423-5p suppressed the HG-induced increases in cell viability, migration, and angiogenesis. E2F1 transcriptionally activated miR-423-5p expression and miR-423-5p mimics blocked the effects of E2F1 knockdown on angiogenesis. Moreover, miR-423-5p directly targeted HIPK2 to disinhibit HIF1α/VEGF signaling. Knockdown of HIPK2 reversed the effects of miR-423-5p inhibitor on cell viability, migration, and angiogenesis. Knockdown of E2F1 suppressed neovascularization during DR in vivo. CONCLUSIONS: E2F1 activates miR-423-5p transcription during DR to promote angiogenesis via suppressing HIPK2 expression to disinhibit HIF1α/VEGF signaling. Strategies targeting E2F1/miR-423-5p/HIPK2 axis could be potentially used for DR treatment. BioMed Central 2021-12-28 /pmc/articles/PMC8715594/ /pubmed/34963484 http://dx.doi.org/10.1186/s13098-021-00769-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Xiao, Qing
Zhao, Yinu
Sun, Hongjing
Xu, Jia
Li, Wenjie
Gao, Limo
MiR-423-5p activated by E2F1 promotes neovascularization in diabetic retinopathy by targeting HIPK2
title MiR-423-5p activated by E2F1 promotes neovascularization in diabetic retinopathy by targeting HIPK2
title_full MiR-423-5p activated by E2F1 promotes neovascularization in diabetic retinopathy by targeting HIPK2
title_fullStr MiR-423-5p activated by E2F1 promotes neovascularization in diabetic retinopathy by targeting HIPK2
title_full_unstemmed MiR-423-5p activated by E2F1 promotes neovascularization in diabetic retinopathy by targeting HIPK2
title_short MiR-423-5p activated by E2F1 promotes neovascularization in diabetic retinopathy by targeting HIPK2
title_sort mir-423-5p activated by e2f1 promotes neovascularization in diabetic retinopathy by targeting hipk2
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715594/
https://www.ncbi.nlm.nih.gov/pubmed/34963484
http://dx.doi.org/10.1186/s13098-021-00769-7
work_keys_str_mv AT xiaoqing mir4235pactivatedbye2f1promotesneovascularizationindiabeticretinopathybytargetinghipk2
AT zhaoyinu mir4235pactivatedbye2f1promotesneovascularizationindiabeticretinopathybytargetinghipk2
AT sunhongjing mir4235pactivatedbye2f1promotesneovascularizationindiabeticretinopathybytargetinghipk2
AT xujia mir4235pactivatedbye2f1promotesneovascularizationindiabeticretinopathybytargetinghipk2
AT liwenjie mir4235pactivatedbye2f1promotesneovascularizationindiabeticretinopathybytargetinghipk2
AT gaolimo mir4235pactivatedbye2f1promotesneovascularizationindiabeticretinopathybytargetinghipk2